Skip to main content

Table 1 Patient demographics and clinical characteristics at baseline by tocilizumab and abatacept initiators

From: Comparative effectiveness of abatacept versus tocilizumab in rheumatoid arthritis patients with prior TNFi exposure in the US Corrona registry

Characteristic Unmatched Matched
TCZ Initiators ABA Initiators Standardized differencea TCZ Initiators ABA Initiators Standardized differencea
(n = 264) (n = 663) ABA – TCZ (n = 264) (n = 264) ABA – TCZ
Female, n (%) 197 (74.6) 547 (82.9) 0.2 197 (74.6) 197 (74.6) 0
Age, mean ± SD 56.6 ± 12.4 57.3 ± 12.3 0.05 56.6 ± 12.4 56.6 ± 12.2 –0.01
Race: White, n (%) 201 (76.1) 513 (77.4) 0.03 201 (76.1) 211 (79.9) 0.09
Smoker, n (%)
 Never 119 (45.1) 305 (46.1) 0.07 119 (45.1) 115 (43.6) 0.03
 Previous 90 (34.1) 237 (35.8)   90 (34.1) 94 (35.6)  
 Current 55 (20.8) 119 (18.0)   55 (20.8) 55 (20.8)  
Insuranceb, n (%)
 Private 205 (77.6) 516 (77.8) 0.01 205 (77.6) 193 (73.1) –0.1
 Medicaid 12 (4.5) 34 (5.1) 0.03 12 (4.5) 14 (5.3) 0.03
 Medicare 96 (36.4) 210 (31.7) –0.1 96 (36.4) 92 (34.8) –0.03
 None 3 (1.1) 10 (1.5) 0.03 3 (1.1) 6 (2.2) 0.09
Duration of RA, mean ± SD 10.7 ± 8.8 11.1 ± 9.3 0.03 10.7 ± 8.8 10.3 ± 10.0 –0.03
RF/CCP seropositivity, n (%) 127 (76.5) 291 (74.1) –0.06 127 (76.5) 135 (73.7) –0.06
History of comorbidities, n (%)
 Cardiovascular 43 (16.3) 88 (13.3) –0.08 43 (16.3) 41 (15.5) –0.02
 Malignancy 14 (5.3) 37 (5.6) 0.01 14 (5.3) 16 (6.1) 0.03
 Serious infection 18 (6.8) 67 (10.1) 0.12 18 (6.8) 23 (8.7) 0.07
 Diabetes 26 (9.9) 64 (9.7) –0.01 26 (9.9) 33 (12.5) 0.08
mHAQ, mean ± SD 0.7 ± 0.5 0.6 ± 0.5 –0.16 0.7 ± 0.5 0.7 ± 0.5 0.02
CDAI, mean ± SD 27.8 ± 12.1 27.1 ± 11.9 –0.05 27.8 ± 12.1 28.1 ± 12.8 0.04
Tender joints, mean ± SD 10.3 ± 7.6 10.0 ± 7.2 –0.05 10.3 ± 7.6 10.4 ± 7.5 0.001
Swollen joints, mean ± SD 7.0 ± 4.9 7.4 ± 5.6 0.08 7.0 ± 4.9 7.3 ± 5.8 0.05
Physician global, mean ± SD 47.2 ± 20.4 43.8 ± 20.5 –0.16 47.2 ± 20.4 47.7 ± 20.9 0.02
Patient global, mean ± SD 57.0 ± 23.6 53.2 ± 23.9 –0.16 57.0 ± 23.6 56.8 ± 23.3 0
Patient pain, mean ± SD 58.6 ± 24.6 55.9 ± 25.4 –0.1 58.6 ± 24.6 58.3 ± 25.5 –0.01
ACR functional status, n (%)
 I 55 (20.8) 200 (30.2)   55 (20.8) 48 (18.2)  
 II 130 (49.2) 306 (46.2) 0.23 130 (49.2) 138 (52.3) 0.07
 III/IV 79 (29.0) 157 (23.7)   79 (29.9) 78 (29.5)  
Prednisone use, n (%)
 None 166 (63.4) 415 (63.1)   166 (63.4) 168 (63.9)  
 <10 mg 53 (20.2) 144 (21.9) 0.04 53 (20.2) 50 (18.8) 0.03
 ≥10 mg 43 (16.4) 99 (15.1)   43 (16.4) 44 (16.5)  
Number of prior biologics used, n (%)
 1 99 (37.5) 261 (39.4) 0.12 99 (37.5) 109 (41.3) –0.08
 2 94 (35.6) 257 (38.8)   165 (62.5) 155 (58.7)  
 3+ 71 (26.9) 145 (21.8)     
Concomitant use of cDMARD, n (%) 180 (68.2) 456 (68.8) 0.01 180 (68.2) 179 (67.8) –0.01
  1. aA standard difference < 0.1 has been taken to indicate a negligible difference in the mean or prevalence of a covariate between treatment groups
  2. bpatients may have more than 1 type of insurance
  3. ABA abatacept, ACR American College of Rheumatology, CCP cyclic citrullinated peptide, CDAI Clinical Disease Activity Index, cDMARD conventional disease-modifying anti-rheumatic agent, mHAQ modified health assessment questionnaire, RA rheumatoid arthritis, RF rheumatoid factor, TCZ tocilizumab